The global mycoplasma testing market size is expected to reach USD 2.26 billion by 2030, registering a CAGR of 13.58% over the forecast period, according to a new report by Grand View Research, Inc. The major factors driving the expansion of market includes growing demand for mycoplasma testing in bio manufacturing, emerging economies, and growing pharmaceutical outsourcing. Additionally, the market's overall growth is driven by rising cell-line contamination and innovation & research in biological sciences.

Growing number of government initiatives to support pharmaceutical and biotechnology companies is also driving the market growth. The U.S. FDA proposed to remove a test for detecting mycoplasma within in vitro living cell cultures, as it can help identify only a single test method. These changes in biologics regulations are anticipated to improve specificity and sensitivity in mycoplasma detection tests, leading to introduction of new technologies in the industry. This is expected to create immense opportunities for key players in new product development.

The rates of M. pneumoniae positivity sharply decreased during the COVID-19 pandemic outbreak at the end of 2019. This was a result of the COVID-19 pandemic's stringent regulations, which successfully stopped the spread of M. pneumonia. However, it is anticipated that M. pneumonia will expand even more throughout the research period following the relaxation of COVID-19 limits, which will have a positive impact on the mycoplasma testing market's growth.

Gather more insights about the market drivers, restrains and growth of the Mycoplasma Testing Market

Mycoplasma Testing Market Report Highlights

• By product, kits and reagents dominated the market, and are anticipated to exhibit the fastest CAGR throughout the forecast period, due to their widespread use in mycoplasma testing

• Ease of conducting the procedure and rapid detection are some of the major advantages offered by the PCR method

• By application, the cell line testing segment held a largest share of 41.65% in 2023, owing to the increase in research projects being done in the field of cell culture

• Mycoplasma contamination can cause alterations in cell culture metabolites and lead to development of toxins. This increases the importance of cell line testing and authentication in the pharmaceutical and biopharmaceutical industries

• North America held the largest share of 39.04% in 2023. This is mostly attributed to the presence of significant market participants, as well as rising R&D spending and federal assistance

• In Asia Pacific, the market is expected to grow at the highest rate in a projected time period driven by factors such as the rising prevalence of target diseases with an aging population, rising awareness and others

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

• The global saliva collection and diagnostics market size was estimated at USD 818.9 million in 2024 and is projected to grow at a CAGR of 4.7% from 2025 to 2030. 

• The global diagnostic enzymes market size was valued at USD 5.15 billion in 2024 and is anticipated to grow at a CAGR of 7.1% from 2025 to 2030.

Mycoplasma Testing Market Segmentation 

Grand View Research has segmented the global mycoplasma testing market on the basis of product, technology, application, end-use, and region:

Mycoplasma Testing Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments

• Kits & Reagents

o PCR Assays

o Nucleic Acid Detection Kits

o Stains

o Elimination Kits

o Standards & Controls

o Others

• Services

Mycoplasma Testing Technology Outlook (Revenue, USD Million, 2018 - 2030)

• PCR

• ELISA

• Direct Assay

• Indirect Assay

• Microbial Culture Techniques

• Enzymatic Methods

Mycoplasma Testing Application Outlook (Revenue, USD Million, 2018 - 2030)

• Cell Line Testing

• Virus Testing

• End of Production Cells Testing

• Others

Mycoplasma Testing End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Academic Research Institutes

• Cell Banks

• Contract Research Organizations

• Pharmaceutical & Biotechnology Companies

• Others

Mycoplasma Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o UK

o Spain

o France

o Italy

o Denmark

o Sweden

o Norway

o Russia

• Asia Pacific

o Japan

o China

o India

o South Korea

o Thailand

o Australia

o Singapore

• Latin America

o Brazil

o Mexico

o Argentina

• MEA

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Order a free sample PDF of the Mycoplasma Testing Market Intelligence Study, published by Grand View Research.